Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT04262492
Recruiting Observational

International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants

NCT04262492 · tracked via the Priya Life Science France tracker
Sponsor
Stéphane Zuily
Phase
Observational
Started
2020-10-21
Last updated
2026-05-08

Condition(s) studied

Antiphospholipid SyndromeThrombosisAnticoagulants Causing Adverse Effects in Therapeutic Use

Investigational drug(s) / intervention(s)

Rivaroxaban →

Rivaroxaban: Rivaroxaban 10 mg or 15 mg or 20 mg OD Dabigatran 110 mg or 150 mg BID Apixaban 2.5 mg or 5 mg or 10 mg BID

Study summary

This registry, currently being established will ensure consistency of data collection and provide safety information in non high-risk APS patients currently on DOACs.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient receiving a comprehensive information about the study, and not opposed to participate * Age ≥ 18 yo * Classification of definite APS according to revised Sapporo-Sydney criteria * Direct oral anticoagulant treatment prescribed during at least 6 months or with the possibility of follow-up of at least 6 months Exclusion Criteria: * Incomplete revised Sapporo-Sydney criteria * No data regarding the recurrent thrombosis * Pregnant woman * Age \< 18 yo

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Stéphane Zuily Nancy France Recruiting

On this site

📄 Xarelto (rivaroxaban) drug profile →

Other trials for the same condition

Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS) Recruiting
Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies Recruiting
Platelets and Extracorporeal Membrane Oxygenation Veno-venous Starting soon
Adverse Drug Events in Patients on Oral Anticoagulation in the Emergency Department Recruiting
Laboratory and Clinical Data in Antiphospholipid Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04262492 on ClinicalTrials.gov ↗ ← All trials in France